EGFR and hepatocellular carcinoma: developed dacomitinib-based EGFR degraders, with PROTAC 13 (Figure 14) showing potent degradation of EGFRdel19 (DC50 = 3.57 nM; IC50 = 6 nM; for dacomitinib: IC50 = 7 nM) in HCC-827 cells, while displaying minimal activity against other EGFR mutants (e.g. L858R/T790M) and EGFRWT-expressing lines (A549, A431), as well as HER2/HER4 ((IC50 > 20 μM EGFR mutants and wild-type; for dacomitinib: IC50 = 700 nM; 1.79 μM; 1.96 μM; respectively).